Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 11/20 | 0.63 |
| ▸ | SLC6A3 | Q01959 | 10/20 | 0.63 |
| ▸ | SLC6A2 | P23975 | 6/20 | 0.58 |
| ▸ | DRD2 | P14416 | 2/20 | 0.45 |
| ▸ | DRD4 | P21917 | 1/20 | 0.45 |
| ▸ | DRD3 | P35462 | 1/20 | 0.45 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.44 |
| ▸ | PRKAB2 | O43741 | 2/20 | 0.42 |
| ▸ | PRKAG1 | P54619 | 2/20 | 0.42 |
| ▸ | PRKAA2 | P54646 | 2/20 | 0.42 |
| ▸ | PRKAA1 | Q13131 | 2/20 | 0.42 |
| ▸ | PRKAG3 | Q9UGI9 | 2/20 | 0.42 |
| ▸ | PRKAG2 | Q9UGJ0 | 2/20 | 0.42 |
| ▸ | PRKAB1 | Q9Y478 | 2/20 | 0.42 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28438976 | 0.98 | SLC6A4 (0.67) | SLC6A4SLC6A3SLC6A2DRD2DRD4 | |
| SCHEMBL2129 | 0.96 | SLC6A4 (0.58) | SLC6A4SLC6A3SLC6A2DRD2DRD4 | |
| SCHEMBL3615305 | 0.91 | SLC6A4 (0.52) | SLC6A4SLC6A3SLC6A2DRD2DRD4 | |
| SCHEMBL10633566 | 0.82 | SLC6A3 (0.62) | SLC6A4SLC6A3SLC6A2HDAC4HSD11B1 | |
| SCHEMBL188283 | 0.82 | SLC6A4 (0.60) | SLC6A4SLC6A3SLC6A2DRD2DRD4 | |
| SCHEMBL11826316 | 0.81 | PDE4A (0.45) | SLC6A4SLC6A3SLC6A2DRD2DRD4 | |
| SCHEMBL16565548 | 0.80 | P2RX7 (0.52) | SLC6A4SLC6A3SLC6A2DRD2DRD4 | |
| SCHEMBL21078008 | 0.80 | DRD2 (0.49) | SLC6A4SLC6A3SLC6A2DRD2DRD4 | |
| SCHEMBL9804270 | 0.79 | SLC6A4 (0.44) | SLC6A4SLC6A3SLC6A2DRD2DRD4 | |
| SCHEMBL3891504 | 0.79 | SLC6A3 (0.63) | SLC6A4SLC6A3SLC6A2HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6989052-B1 | Phase change ink printing process | XEROX CORPORATION (US) | 2006-01-24 | — | — | US | claimed |
| US-20060004123-A1 | PHASE CHANGE INK PRINTING PROCESS | XEROX CORPORATION | 2006-01-05 | — | — | US | claimed |
| US-5922117-A | Ink compositions containing alcohols | XEROX CORPORATION (US) | 1999-07-13 | — | — | US | claimed |
| EP-3426246-B1 | THIAZOLIDINONE COMPOUNDS AND USE THEREOF | NATIONAL HEALTH RES INST (TW) | 2024-05-01 | — | — | EP | disclosed |
| US-10544113-B2 | Thiazolidinone compounds and use thereof | NATIONAL HEALTH RESEARCH INSTITUTE (TW) | 2020-01-28 | — | — | US | disclosed |
| US-10544113-B2 | Thiazolidinone compounds and use thereof | NATIONAL HEALTH RESEARCH INSTITUTE (TW) | 2020-01-28 | — | — | US | disclosed |
| EP-3426246-A1 | THIAZOLIDINONE COMPOUNDS AND USE THEREOF | National Health Research Institutes (TW) | 2019-01-16 | — | — | EP | disclosed |
| CN-108883099-A | THIAZOLIDINONE COMPOUNDS AND USE THEREOF | 石全 | 2018-11-23 | — | — | CN | disclosed |
| WO-2017155910-A1 | THIAZOLIDINONE COMPOUNDS AND USE THEREOF | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2017-09-14 | — | — | WO | disclosed |
| WO-2017155910-A1 | THIAZOLIDINONE COMPOUNDS AND USE THEREOF | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2017-09-14 | — | — | WO | disclosed |
| US-20170253569-A1 | THIAZOLIDINONE COMPOUNDS AND USE THEREOF | REGENTS OF THE UNIVERSITY OF MINNESOTA | 2017-09-07 | — | — | US | disclosed |
| US-20140194431-A1 | PYRIMIDONE DERIVATIVES AND THEIR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF A VIRAL DISEASE | SAVIRA PHARMACEUTICALS GMBH (AT) | 2014-07-10 | — | — | US | disclosed |
| US-6989052-B1 | Phase change ink printing process | XEROX CORPORATION (US) | 2006-01-24 | — | — | US | disclosed |
| US-20060004123-A1 | PHASE CHANGE INK PRINTING PROCESS | XEROX CORPORATION | 2006-01-05 | — | — | US | disclosed |
| EP-0976734-B1 | Selective inhibitors of viral or bacterial neuraminidase | GILEAD SCIENCES INC (US) | 2005-09-28 | — | — | EP | disclosed |
| EP-0759917-B1 | NOVEL SELECTIVE INHIBITORS OF VIRAL OR BACTERIAL NEURAMINIDASES | GILEAD SCIENCES INC (US) | 2000-04-12 | — | — | EP | disclosed |
| US-5922117-A | Ink compositions containing alcohols | XEROX CORPORATION (US) | 1999-07-13 | — | — | US | disclosed |
| WO-1998020878-A1 | 5-[φ-(SUBSTITUTED ARYL)ALKENYLENE AND ALKYNYLENE]-2,4-DIAMINOPYRIMIDINES AS PESTICIDES | FMC CORPORATION (US) | 1998-05-22 | — | — | WO | disclosed |
| US-5696259-A | 2,4-diamino-5-iodopyrimidines useful as pesticide intermediates | FMC CORPORATION (US) | 1997-12-09 | — | — | US | disclosed |
| US-5622954-A | INSECTICIDE | FMC CORPORATION (US) | 1997-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10544113-B2 | Thiazolidinone compounds and use thereof | OPRL1, OPRD1, OPRK1 | SLC6A4 354/4885SLC6A3 220/4885SLC6A2 559/4885 |
| US-20140194431-A1 | PYRIMIDONE DERIVATIVES AND THEIR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF A VIRAL DISEASE | TPMT, XDH, DPYD | SLC6A4 359/4885SLC6A3 130/4885SLC6A2 276/4885 |
| US-20170253569-A1 | THIAZOLIDINONE COMPOUNDS AND USE THEREOF | OPRL1, OPRD1, OPRK1 | SLC6A4 354/4885SLC6A3 220/4885SLC6A2 559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.